AQR Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

AQR Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13,138	Closed	-$125K	–	2265
2018 Q4	$125K	Sell	13,138 -1,741	-12%	-$22.6K	﹤0.01%	2133
2018 Q3	$247K	Buy	14,879 +836	+6%	+$13.4K	﹤0.01%	2155
2018 Q2	$225K	Hold	14,043	–	–	﹤0.01%	2195
2018 Q1	$215K	Hold	14,043	–	–	﹤0.01%	2127
2017 Q4	$219K	Sell	14,043 -5,031	-26%	-$67.3K	﹤0.01%	2136
2017 Q3	$212K	Sell	19,074 -6,488	-25%	-$61K	﹤0.01%	2160
2017 Q2	$235K	Hold	25,562	–	–	﹤0.01%	2091
2017 Q1	$219K	Buy	+25,562	New	+$233K	﹤0.01%	2087
2014 Q4	–	Sell	-10,400	Closed	-$130K	–	2675
2014 Q3	$130K	Sell	10,400 -10,400	-50%	-$128K	﹤0.01%	2421
2014 Q2	$305K	Buy	+20,800	New	+$319K	﹤0.01%	2207

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

AQR Capital Management's STML Position: Q1 2019 in Review

AQR Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2019, closing a stake of 13,138 shares — an estimated $125K sold.

AQR Capital Management first reported a position in STML in Q2 2014 and held it in 10 quarters. The position peaked at $305K in Q2 2014. 98 funds tracked by Wall St. Rank hold STML as of Q1 2019.

AQR Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
AQR Capital Management sold 13,138 Stemline Therapeutics, Inc. shares in Q1 2019, an estimated $125K.
AQR Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 10 quarters.
AQR Capital Management's Stemline Therapeutics, Inc. position peaked at $305K in Q2 2014.
98 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2019.

Based on AQR Capital Management's 13F filing for Q1 2019, filed 14 May 2019.